메뉴 건너뛰기




Volumn 65, Issue 2, 2013, Pages 529-538

Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; PLACEBO;

EID: 84873850049     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37734     Document Type: Article
Times cited : (158)

References (55)
  • 1
    • 67049165566 scopus 로고    scopus 로고
    • Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study
    • Younger J, Mackey S,. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009; 10: 663-72.
    • (2009) Pain Med , vol.10 , pp. 663-672
    • Younger, J.1    MacKey, S.2
  • 3
    • 79959725500 scopus 로고    scopus 로고
    • Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial
    • Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011; 56: 2088-97.
    • (2011) Dig Dis Sci , vol.56 , pp. 2088-2097
    • Smith, J.P.1    Bingaman, S.I.2    Ruggiero, F.3    Mauger, D.T.4    Mukherjee, A.5    McGovern, C.O.6
  • 4
    • 77955296499 scopus 로고    scopus 로고
    • Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    • Cree BA, Kornyeyeva E, Goodin DS,. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010; 68: 145-50.
    • (2010) Ann Neurol , vol.68 , pp. 145-150
    • Cree, B.A.1    Kornyeyeva, E.2    Goodin, D.S.3
  • 5
    • 77955144319 scopus 로고    scopus 로고
    • The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: A randomized placebo-controlled trial
    • Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B,. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010; 16: 964-9.
    • (2010) Mult Scler , vol.16 , pp. 964-969
    • Sharafaddinzadeh, N.1    Moghtaderi, A.2    Kashipazha, D.3    Majdinasab, N.4    Shalbafan, B.5
  • 7
    • 59249086604 scopus 로고    scopus 로고
    • Low-dose naltrexone for disease prevention and quality of life
    • Brown N, Panksepp J,. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009; 72: 333-7.
    • (2009) Med Hypotheses , vol.72 , pp. 333-337
    • Brown, N.1    Panksepp, J.2
  • 8
    • 54049124717 scopus 로고    scopus 로고
    • Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of Toll-like receptor 4 (TLR4)
    • Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4 (TLR4). Eur J Neurosci 2008; 28: 20-9.
    • (2008) Eur J Neurosci , vol.28 , pp. 20-29
    • Hutchinson, M.R.1    Zhang, Y.2    Brown, K.3    Coats, B.D.4    Shridhar, M.5    Sholar, P.W.6
  • 9
    • 0034015558 scopus 로고    scopus 로고
    • Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation
    • Liu B, Du L, Hong JS,. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000; 293: 607-17.
    • (2000) J Pharmacol Exp Ther , vol.293 , pp. 607-617
    • Liu, B.1    Du, L.2    Hong, J.S.3
  • 10
    • 77950844003 scopus 로고    scopus 로고
    • Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats
    • Mattioli TA, Milne B, Cahill CM,. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010; 6: 22.
    • (2010) Mol Pain , vol.6 , pp. 22
    • Mattioli, T.A.1    Milne, B.2    Cahill, C.M.3
  • 11
    • 73049110767 scopus 로고    scopus 로고
    • The multifaceted profile of activated microglia
    • Lynch MA,. The multifaceted profile of activated microglia. Mol Neurobiol 2009; 40: 139-56.
    • (2009) Mol Neurobiol , vol.40 , pp. 139-156
    • Lynch, M.A.1
  • 14
    • 57849100261 scopus 로고    scopus 로고
    • Proinflammatory cytokines and sickness behavior: Implications for depression and cancer-related symptoms
    • Myers JS,. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008; 35: 802-7.
    • (2008) Oncol Nurs Forum , vol.35 , pp. 802-807
    • Myers, J.S.1
  • 15
    • 0028890678 scopus 로고
    • The prevalence and characteristics of fibromyalgia in the general population
    • Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L,. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
    • (1995) Arthritis Rheum , vol.38 , pp. 19-28
    • Wolfe, F.1    Ross, K.2    Anderson, J.3    Russell, I.J.4    Hebert, L.5
  • 16
    • 0025266660 scopus 로고
    • The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee
    • Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
    • (1990) Arthritis Rheum , vol.33 , pp. 160-172
    • Wolfe, F.1    Smythe, H.A.2    Yunus, M.B.3    Bennett, R.M.4    Bombardier, C.5    Goldenberg, D.L.6
  • 17
    • 77951735184 scopus 로고    scopus 로고
    • The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity
    • Wolfe F, Clauw DJ, FitzCharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600-10.
    • (2010) Arthritis Care Res (Hoboken) , vol.62 , pp. 600-610
    • Wolfe, F.1    Clauw, D.J.2    Fitzcharles, M.A.3    Goldenberg, D.L.4    Katz, R.S.5    Mease, P.6
  • 18
    • 80755169569 scopus 로고    scopus 로고
    • Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia
    • Staud R,. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep 2011; 13: 513-20.
    • (2011) Curr Rheumatol Rep , vol.13 , pp. 513-520
    • Staud, R.1
  • 19
    • 79951579664 scopus 로고    scopus 로고
    • Central sensitization: Implications for the diagnosis and treatment of pain
    • Woolf CJ,. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-15.
    • (2011) Pain , vol.152
    • Woolf, C.J.1
  • 20
    • 0026165648 scopus 로고
    • The fibromyalgia impact questionnaire: Development and validation
    • Burckhardt CS, Clark SR, Bennett RM,. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728-33.
    • (1991) J Rheumatol , vol.18 , pp. 728-733
    • Burckhardt, C.S.1    Clark, S.R.2    Bennett, R.M.3
  • 21
    • 0029803149 scopus 로고    scopus 로고
    • Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
    • Beck AT, Steer RA, Ball R, Ranieri W,. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67: 588-97.
    • (1996) J Pers Assess , vol.67 , pp. 588-597
    • Beck, A.T.1    Steer, R.A.2    Ball, R.3    Ranieri, W.4
  • 22
    • 33750840583 scopus 로고    scopus 로고
    • Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations
    • Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 2006; 125: 208-15.
    • (2006) Pain , vol.125 , pp. 208-215
    • Turk, D.C.1    Dworkin, R.H.2    Burke, L.B.3    Gershon, R.4    Rothman, M.5    Scott, J.6
  • 24
    • 77957224119 scopus 로고    scopus 로고
    • Pain intensity and duration can be enhanced by prior challenge: Initial evidence suggestive of a role of microglial priming
    • Hains LE, Loram LC, Weiseler JL, Frank MG, Bloss EB, Sholar P, et al. Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain 2010; 11: 1004-14.
    • (2010) J Pain , vol.11 , pp. 1004-1014
    • Hains, L.E.1    Loram, L.C.2    Weiseler, J.L.3    Frank, M.G.4    Bloss, E.B.5    Sholar, P.6
  • 25
    • 54249124166 scopus 로고    scopus 로고
    • Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system
    • Dilger RN, Johnson RW,. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 2008; 84: 932-9.
    • (2008) J Leukoc Biol , vol.84 , pp. 932-939
    • Dilger, R.N.1    Johnson, R.W.2
  • 26
    • 79961033108 scopus 로고    scopus 로고
    • Diesel exhaust activates and primes microglia: Air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity
    • Levesque S, Taetzsch T, Lull ME, Kodavanti U, Stadler K, Wagner A, et al. Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity. Environ Health Perspect 2011; 119: 1149-55.
    • (2011) Environ Health Perspect , vol.119 , pp. 1149-1155
    • Levesque, S.1    Taetzsch, T.2    Lull, M.E.3    Kodavanti, U.4    Stadler, K.5    Wagner, A.6
  • 27
    • 33646558560 scopus 로고    scopus 로고
    • Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis
    • Carvey PM, Punati A, Newman MB,. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 2006; 15: 239-50.
    • (2006) Cell Transplant , vol.15 , pp. 239-250
    • Carvey, P.M.1    Punati, A.2    Newman, M.B.3
  • 28
    • 0036718166 scopus 로고    scopus 로고
    • Fatigue is associated with high circulating leptin levels in chronic hepatitis C
    • Piche T, Gelsi E, Schneider SM, Hebuterne X, Giudicelli J, Ferrua B, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002; 51; 434-9.
    • (2002) Gut , vol.51 , pp. 434-439
    • Piche, T.1    Gelsi, E.2    Schneider, S.M.3    Hebuterne, X.4    Giudicelli, J.5    Ferrua, B.6
  • 29
    • 0141740195 scopus 로고    scopus 로고
    • Effects of leptin on the production of cytokines by cultured human endometrial stromal and epithelial cells
    • Fukuda J, Nasu K, Sun B, Shang S, Kawano Y, Miyakawa I,. Effects of leptin on the production of cytokines by cultured human endometrial stromal and epithelial cells. Fertil Steril 2003; 80 Suppl 2: 783-7.
    • (2003) Fertil Steril , vol.80 , Issue.SUPPL. 2 , pp. 783-787
    • Fukuda, J.1    Nasu, K.2    Sun, B.3    Shang, S.4    Kawano, Y.5    Miyakawa, I.6
  • 30
    • 53549122734 scopus 로고    scopus 로고
    • Chemokines as pain mediators and modulators
    • White FA, Wilson NM,. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol 2008; 21: 580-5.
    • (2008) Curr Opin Anaesthesiol , vol.21 , pp. 580-585
    • White, F.A.1    Wilson, N.M.2
  • 31
    • 38049150644 scopus 로고    scopus 로고
    • Chemokines and the pathophysiology of neuropathic pain
    • White FA, Jung H, Miller RJ,. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 2007; 104: 20151-8.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 20151-20158
    • White, F.A.1    Jung, H.2    Miller, R.J.3
  • 32
    • 47349104717 scopus 로고    scopus 로고
    • Circulating cytokine levels compared to pain in patients with fibromyalgia - A prospective longitudinal study over 6 months
    • Wang H, Moser M, Schiltenwolf M, Buchner M,. Circulating cytokine levels compared to pain in patients with fibromyalgia-a prospective longitudinal study over 6 months. J Rheumatol 2008; 35: 1366-70.
    • (2008) J Rheumatol , vol.35 , pp. 1366-1370
    • Wang, H.1    Moser, M.2    Schiltenwolf, M.3    Buchner, M.4
  • 34
    • 12344328556 scopus 로고    scopus 로고
    • Immune-to-brain communication dynamically modulates pain: Physiological and pathological consequences
    • Wieseler-Frank J, Maier SF, Watkins LR,. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 2005; 19: 104-11.
    • (2005) Brain Behav Immun , vol.19 , pp. 104-111
    • Wieseler-Frank, J.1    Maier, S.F.2    Watkins, L.R.3
  • 35
    • 70350554076 scopus 로고    scopus 로고
    • Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: A new paradigm for the treatment of multiple sclerosis
    • Zagon IS, Rahn KA, Turel AP, McLaughlin PJ,. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) 2009; 234: 1383-92.
    • (2009) Exp Biol Med (Maywood) , vol.234 , pp. 1383-1392
    • Zagon, I.S.1    Rahn, K.A.2    Turel, A.P.3    McLaughlin, P.J.4
  • 36
    • 0035929507 scopus 로고    scopus 로고
    • Up-regulation of spinal μ-opioid receptor function to activate G-protein by chronic naloxone treatment
    • Narita M, Mizoguchi H, Nagase H, Suzuki T, Tseng LF,. Up-regulation of spinal μ-opioid receptor function to activate G-protein by chronic naloxone treatment. Brain Res 2001; 913: 170-3.
    • (2001) Brain Res , vol.913 , pp. 170-173
    • Narita, M.1    Mizoguchi, H.2    Nagase, H.3    Suzuki, T.4    Tseng, L.F.5
  • 37
    • 0142105502 scopus 로고    scopus 로고
    • Chronic opioid antagonist treatment dose-dependently regulates μ-opioid receptors and trafficking proteins in vivo
    • Rajashekara V, Patel CN, Patel K, Purohit V, Yoburn BC,. Chronic opioid antagonist treatment dose-dependently regulates μ-opioid receptors and trafficking proteins in vivo. Pharmacol Biochem Behav 2003; 75: 909-13.
    • (2003) Pharmacol Biochem Behav , vol.75 , pp. 909-913
    • Rajashekara, V.1    Patel, C.N.2    Patel, K.3    Purohit, V.4    Yoburn, B.C.5
  • 39
    • 34248665817 scopus 로고    scopus 로고
    • Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes
    • Yunus MB,. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339-56.
    • (2007) Semin Arthritis Rheum , vol.36 , pp. 339-356
    • Yunus, M.B.1
  • 40
    • 84861509893 scopus 로고    scopus 로고
    • The prevalence of fibromyalgia in other chronic pain conditions
    • Yunus MB,. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat 2012; 2012: 584573.
    • (2012) Pain Res Treat , vol.2012 , pp. 584573
    • Yunus, M.B.1
  • 41
    • 77957072864 scopus 로고    scopus 로고
    • The temporal dynamics of poststroke neuroinflammation: A longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke
    • Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, Schirrmacher R, et al. The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med 2010; 51: 1404-12.
    • (2010) J Nucl Med , vol.51 , pp. 1404-1412
    • Thiel, A.1    Radlinska, B.A.2    Paquette, C.3    Sidel, M.4    Soucy, J.P.5    Schirrmacher, R.6
  • 42
    • 78651422988 scopus 로고    scopus 로고
    • Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study
    • Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011; 32: 258-70.
    • (2011) Hum Brain Mapp , vol.32 , pp. 258-270
    • Politis, M.1    Pavese, N.2    Tai, Y.F.3    Kiferle, L.4    Mason, S.L.5    Brooks, D.J.6
  • 44
    • 33750487477 scopus 로고    scopus 로고
    • A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice
    • Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, et al. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006; 48: 1871-9.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 1871-1879
    • Liu, S.L.1    Li, Y.H.2    Shi, G.Y.3    Chen, Y.H.4    Huang, C.W.5    Hong, J.S.6
  • 45
    • 21544475536 scopus 로고    scopus 로고
    • MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity
    • Thomas DM, Kuhn DM,. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005; 1050: 190-8.
    • (2005) Brain Res , vol.1050 , pp. 190-198
    • Thomas, D.M.1    Kuhn, D.M.2
  • 46
    • 20044379940 scopus 로고    scopus 로고
    • 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity
    • Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005; 19: 395-7.
    • (2005) FASEB J , vol.19 , pp. 395-397
    • Zhang, W.1    Qin, L.2    Wang, T.3    Wei, S.J.4    Gao, H.M.5    Liu, J.6
  • 47
    • 1242284201 scopus 로고    scopus 로고
    • Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia
    • Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004; 46: 404-11.
    • (2004) Neuropharmacology , vol.46 , pp. 404-411
    • Mizuno, T.1    Kurotani, T.2    Komatsu, Y.3    Kawanokuchi, J.4    Kato, H.5    Mitsuma, N.6
  • 48
    • 79961128957 scopus 로고    scopus 로고
    • Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord
    • Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W,. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis 2011; 44: 63-72.
    • (2011) Neurobiol Dis , vol.44 , pp. 63-72
    • Chechneva, O.V.1    Mayrhofer, F.2    Daugherty, D.J.3    Pleasure, D.E.4    Hong, J.S.5    Deng, W.6
  • 49
    • 78651247933 scopus 로고    scopus 로고
    • MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway
    • Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL,. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med 2011; 17: 64-70.
    • (2011) Nat Med , vol.17 , pp. 64-70
    • Ponomarev, E.D.1    Veremeyko, T.2    Barteneva, N.3    Krichevsky, A.M.4    Weiner, H.L.5
  • 50
    • 70350619625 scopus 로고    scopus 로고
    • A systematic review of adverse events in placebo groups of anti-migraine clinical trials
    • Amanzio M, Corazzini LL, Vase L, Benedetti F,. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261-9.
    • (2009) Pain , vol.146 , pp. 261-269
    • Amanzio, M.1    Corazzini, L.L.2    Vase, L.3    Benedetti, F.4
  • 51
    • 82755162857 scopus 로고    scopus 로고
    • An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia
    • on behalf of the A0081100 Investigators
    • Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al, on behalf of the A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011; 38: 2643-52.
    • (2011) J Rheumatol , vol.38 , pp. 2643-2652
    • Pauer, L.1    Winkelmann, A.2    Arsenault, P.3    Jespersen, A.4    Whelan, L.5    Atkinson, G.6
  • 53
    • 79959997862 scopus 로고    scopus 로고
    • Longterm therapeutic response to milnacipran treatment for fibromyalgia: A European 1-year extension study following a 3-month study
    • on behalf of the Multinational Coordinator Study Group
    • Branco JC, Cherin P, Montagne A, Bouroubi A, on behalf of the Multinational Coordinator Study Group. Longterm therapeutic response to milnacipran treatment for fibromyalgia: a European 1-year extension study following a 3-month study. J Rheumatol 2011; 38: 1403-12.
    • (2011) J Rheumatol , vol.38 , pp. 1403-1412
    • Branco, J.C.1    Cherin, P.2    Montagne, A.3    Bouroubi, A.4
  • 54
    • 77952742362 scopus 로고    scopus 로고
    • Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome
    • Hauser W, Petzke F, Sommer C,. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010; 11: 505-21.
    • (2010) J Pain , vol.11 , pp. 505-521
    • Hauser, W.1    Petzke, F.2    Sommer, C.3
  • 55
    • 84860389712 scopus 로고    scopus 로고
    • A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia
    • Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA,. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011; 41: 335-45.e6.
    • (2011) Semin Arthritis Rheum , vol.41
    • Choy, E.1    Marshall, D.2    Gabriel, Z.L.3    Mitchell, S.A.4    Gylee, E.5    Dakin, H.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.